ada guidelines dpp4 and glp-1 glp 1 recommendations π¨ Diabetes Update 2026 Key highlights from the latest ADA Standards of Care focusing on: βοΈ Achieving glycemic control βοΈ Effective weight management βοΈ Reducing cardiovascular & kidney risk π Key Mechanisms of dipeptidyl peptidaseβ4 (DPPβ4)
Description
Semaglutide 2.4mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection
Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.
The majority of bile acids are actively absorbed via specific transport proteins that are highly expressed in the distal ileum
A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who take GLP-1 medications are about 30% less likely to develop breast cancer than those who do not take GLP-1 medications.
#Pharmacology #ClinicalPharmacology #DrugDiscovery #PharmaResearch #ObesityTreatment #HealthcareInnovation #DrugSafety
